The impact of primary tumor sidedness on survival in early-onset colorectal cancer by stage: A National Veterans Affairs retrospective analysis

被引:14
作者
Azar, Ibrahim [1 ,2 ,3 ]
Al Masalmeh, Nada [2 ]
Esfandiarifard, Saghi [4 ]
Virk, Gurjiwan [3 ]
Kiwan, Wissam [2 ]
Frank Shields, Anthony [1 ,2 ]
Mehdi, Syed [5 ]
Philip, Philip A. [1 ,2 ]
机构
[1] Karmanos Canc Inst, 4100 John R St, Detroit, MI 48201 USA
[2] Wayne State Univ, Detroit, MI USA
[3] Albany Med Coll, Albany, NY 12208 USA
[4] Univ Maryland, Baltimore, MD 21201 USA
[5] Stratton Vet Affairs Med Ctr, Albany, NY USA
关键词
colon cancer; colorectal cancer; early‐ onset colorectal cancer; laterality; left‐ sided colon cancer; primary tumor sidedness; right‐ COLON-CANCER; ADJUVANT CHEMOTHERAPY; MOLECULAR-FEATURES; YOUNG-ADULTS; DISTAL; FLUOROURACIL; DISPARITIES; LEUCOVORIN; DURATION; SURGERY;
D O I
10.1002/cam4.3757
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background The incidence of early-onset colorectal cancer (EOCRC) is rising. Left-sided colorectal cancer (LCC) is associated with better survival compared to right-sided colon cancer (RCC) in metastatic disease. NCCN guidelines recommend the addition of EGFR inhibitors to KRAS/NRAS WT metastatic CRC originating from the left only. Whether laterality impacts survival in locoregional disease and EOCRC is of interest. Methods 65,940 CRC cases from the National VA Cancer Cube Registry (2001-2015) were studied. EOCRC (2096 cases) was defined as CRC diagnosed at <50 years. Using ICD codes, RCC was defined from the cecum to the hepatic flexure (C18.0-C18.3), and LCC from the splenic flexure to the rectum (C18.5-18.7; C19 and C20). Results EOCRC is more likely to originate from the left side (66.65% LCC in EOCRC vs. 58.77% in CRC). Overall, LCC has better 5-year Overall Survival (OS) than RCC in stages I (61.67% vs. 58.01%) and III (46.1% vs. 42.1%) and better 1-year OS in stage IV (57.79% vs. 49.49%). Stage II RCC has better 5-year OS than LCC (53.39% vs. 49.28%). In EOCRC, there is no statistically significant difference between LCC and RCC in stages I-III. Stage IV EOCRC patients with LCC and RCC have a 1-year OS of 73.23% and 59.84%, respectively. Conclusion In EOCRC, LCC is associated with better OS than RCC only stage IV. In the overall population, LCC is associated with better OS in all stages except stage II. The better prognosis of stage II RCC might be due to the high incidence of mismatch repair deficient tumors in this subpopulation.
引用
收藏
页码:2987 / 2995
页数:9
相关论文
共 49 条
[1]   Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer [J].
Andre, T ;
Boni, C ;
Mounedji-Boudiaf, L ;
Navarro, M ;
Tabernero, J ;
Hickish, T ;
Topham, C ;
Zaninelli, M ;
Clingan, P ;
Bridgewater, J ;
Tabah-Fisch, I ;
de Gramont, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2343-2351
[2]  
André T, 2020, LANCET ONCOL, V21, P1620, DOI 10.1016/S1470-2045(20)30527-1
[3]   Increasing Disparities in the Age-Related Incidences of Colon and Rectal Cancers in the United States, 1975-2010 [J].
Bailey, Christina E. ;
Hu, Chung-Yuan ;
You, Nancy ;
Bednarski, Brian K. ;
Rodriguez-Bigas, Miguel A. ;
Skibber, John M. ;
Cantor, Scott B. ;
Chang, George J. .
JAMA SURGERY, 2015, 150 (01) :17-22
[4]  
Blocks, 2018, AM FAM PHYSICIAN, V97, P10
[5]  
Bonithon-Knopp C, 1999, EUR J CANCER PREV, V8, pS3
[6]   COLORECTAL-CANCER - EVIDENCE FOR DISTINCT GENETIC CATEGORIES BASED ON PROXIMAL OR DISTAL TUMOR LOCATION [J].
BUFILL, JA .
ANNALS OF INTERNAL MEDICINE, 1990, 113 (10) :779-788
[7]   Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma: an adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid involvement, and adverse morphologic features [J].
Chang, Daniel T. ;
Pai, Rish K. ;
Rybicki, Lisa A. ;
Dimaio, Michael A. ;
Limaye, Maneesha ;
Jayachandran, Priya ;
Koong, Albert C. ;
Kunz, Pamela A. ;
Fisher, George A. ;
Ford, James M. ;
Welton, Mark ;
Shelton, Andrew ;
Ma, Lisa ;
Arber, Daniel A. ;
Pai, Reetesh K. .
MODERN PATHOLOGY, 2012, 25 (08) :1128-1139
[8]   Duration of Adjuvant Chemotherapy for Stage III Colon Cancer [J].
Grothey, A. ;
Sobrero, A. F. ;
Shields, A. F. ;
Yoshino, T. ;
Paul, J. ;
Taieb, J. ;
Souglakos, J. ;
Shi, Q. ;
Kerr, R. ;
Labianca, R. ;
Meyerhardt, J. A. ;
Vernerey, D. ;
Yamanaka, T. ;
Boukovinas, I. ;
Meyers, J. P. ;
Renfro, L. A. ;
Niedzwiecki, D. ;
Watanabe, T. ;
Torri, V. ;
Saunders, M. ;
Sargent, D. J. ;
Andre, T. ;
Iveson, T. .
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (13) :1177-1188
[9]   The consensus molecular subtypes of colorectal cancer [J].
Guinney, Justin ;
Dienstmann, Rodrigo ;
Wang, Xin ;
de Reynies, Aurelien ;
Schlicker, Andreas ;
Soneson, Charlotte ;
Marisa, Laetitia ;
Roepman, Paul ;
Nyamundanda, Gift ;
Angelino, Paolo ;
Bot, Brian M. ;
Morris, Jeffrey S. ;
Simon, Iris M. ;
Gerster, Sarah ;
Fessler, Evelyn ;
Melo, Felipe De Sousa E. ;
Missiaglia, Edoardo ;
Ramay, Hena ;
Barras, David ;
Homicsko, Krisztian ;
Maru, Dipen ;
Manyam, Ganiraju C. ;
Broom, Bradley ;
Boige, Valerie ;
Perez-Villamil, Beatriz ;
Laderas, Ted ;
Salazar, Ramon ;
Gray, Joe W. ;
Hanahan, Douglas ;
Tabernero, Josep ;
Bernards, Rene ;
Friend, Stephen H. ;
Laurent-Puig, Pierre ;
Medema, Jan Paul ;
Sadanandam, Anguraj ;
Wessels, Lodewyk ;
Delorenzi, Mauro ;
Kopetz, Scott ;
Vermeulen, Louis ;
Tejpar, Sabine .
NATURE MEDICINE, 2015, 21 (11) :1350-1356
[10]  
Hansen IO, 2012, DAN MED J, V59